Amicus Therapeutics Past Earnings Performance
Past criteria checks 0/6
Amicus Therapeutics has been growing earnings at an average annual rate of 6.7%, while the Biotechs industry saw earnings growing at 14.7% annually. Revenues have been growing at an average rate of 31.8% per year.
Key information
6.7%
Earnings growth rate
18.8%
EPS growth rate
| Biotechs Industry Growth | 12.9% |
| Revenue growth rate | 31.8% |
| Return on equity | -192.3% |
| Net Margin | -71.9% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Amicus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 329 | -237 | 213 | 277 |
| 30 Sep 22 | 323 | -264 | 216 | 298 |
| 30 Jun 22 | 321 | -281 | 215 | 285 |
| 31 Mar 22 | 318 | -270 | 204 | 289 |
| 31 Dec 21 | 306 | -250 | 193 | 272 |
| 30 Sep 21 | 294 | -239 | 179 | 266 |
| 30 Jun 21 | 282 | -252 | 171 | 277 |
| 31 Mar 21 | 267 | -254 | 163 | 283 |
| 31 Dec 20 | 261 | -277 | 156 | 308 |
| 30 Sep 20 | 246 | -295 | 156 | 321 |
| 30 Jun 20 | 227 | -293 | 158 | 310 |
| 31 Mar 20 | 209 | -325 | 166 | 311 |
| 31 Dec 19 | 182 | -356 | 170 | 286 |
| 30 Sep 19 | 160 | -345 | 272 | 145 |
| 30 Jun 19 | 131 | -442 | 265 | 224 |
| 31 Mar 19 | 109 | -419 | 251 | 188 |
| 31 Dec 18 | 91 | -349 | 127 | 271 |
| 30 Sep 18 | 73 | -340 | 117 | 251 |
| 30 Jun 18 | 64 | -293 | 106 | 154 |
| 31 Mar 18 | 49 | -279 | 97 | 151 |
| 31 Dec 17 | 37 | -284 | 88 | 141 |
| 30 Sep 17 | 25 | -273 | 82 | 137 |
| 30 Jun 17 | 16 | -208 | 78 | 122 |
| 31 Mar 17 | 9 | -211 | 78 | 109 |
| 31 Dec 16 | 5 | -200 | 71 | 105 |
| 30 Sep 16 | 2 | -184 | 72 | 88 |
Quality Earnings: FOLD * is currently unprofitable.
Growing Profit Margin: FOLD * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: FOLD * is unprofitable, but has reduced losses over the past 5 years at a rate of 6.7% per year.
Accelerating Growth: Unable to compare FOLD *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FOLD * is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-9.8%).
Return on Equity
High ROE: FOLD * has a negative Return on Equity (-192.26%), as it is currently unprofitable.